Daniel A. Kracov and Kathleen E. Means, prominent advisers to drug companies, have left the law firm of Patton Boggs LLP to join the pharmaceutical and medical-device group at Arnold & Porter LLP.
Their move comes at a sensitive time for the drug industry, which faces demands that it control the rising cost of prescription drugs and to submit to tougher safety regulation.
"Dan and Kathy bring great depth, leadership, and energy to the firm," said Michael N. Sohn, chairman at Arnold & Porter.
Kracov was the head of the Food and Drug Administration group at Patton Boggs. At Arnold & Porter, he will be co-leader of the pharmaceutical and medical-device practice group. He is an expert on product approval and crisis management. He has been counsel in several FDA investigations and worked on the reauthorization of the Prescription Drug User Fee Act.
Means will be a a senior policy adviser. At Patton Boggs, she consulted with clients on Medicare and Medicaid, health care finance, insurance, and prescription drug and medical device issues. Means, who is not a lawyer, previously directed the health care staff for the Republican majority on the Senate Finance Committee.
Kracov and Means declined to say whether they were bringing any clients to the firm.
-- Michael S. Rosenwald